Ultragenyx Phase 3 Aspire Trial Of Apazurersen Misses Key Goals In Angelman Syndrome

Ultragenyx reported that its Phase 3 Aspire trial of Apazurersen for Angelman Syndrome did not meet key efficacy goals, resulting in a sharp decline in its stock price.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.